Atea Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. Atea Pharmaceuticals Inc. is based in BOSTON.
Revenue (Most Recent Fiscal Year) | $351.37M |
Net Income (Most Recent Fiscal Year) | $-135.96M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | -- |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.56 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -- |
Net Margin (Trailing 12 Months) | -- |
Return on Equity (Trailing 12 Months) | -23.07% |
Return on Assets (Trailing 12 Months) | -22.04% |
Current Ratio (Most Recent Fiscal Quarter) | 18.24 |
Quick Ratio (Most Recent Fiscal Quarter) | 18.24 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | $6.65 |
Earnings per Share (Most Recent Fiscal Quarter) | $-0.47 |
Earnings per Share (Most Recent Fiscal Year) | $-1.63 |
Diluted Earnings per Share (Trailing 12 Months) | $-1.64 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 84.17M |
Free Float | 71.96M |
Market Capitalization | $314.77M |
Average Volume (Last 20 Days) | 0.29M |
Beta (Past 60 Months) | 0.16 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 14.50% |
Percentage Held By Institutions (Latest 13F Reports) | 86.67% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |